Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.

Yon C, Viswanathan P, Rossignol JF, Korba B.

Antiviral Res. 2011 Sep;91(3):233-40. doi: 10.1016/j.antiviral.2011.05.017. Epub 2011 Jun 14.

2.

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.

Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF.

Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.

PMID:
17888524
3.

Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.

Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR.

Antivir Ther. 2015;20(3):271-80. doi: 10.3851/IMP2850. Epub 2014 Sep 15.

PMID:
25222708
4.

Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.

Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS.

Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. doi: 10.1128/AAC.00078-08. Epub 2008 Aug 18.

5.

Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.

Cheng X, Gao XC, Wang JP, Yang XY, Wang Y, Li BS, Kang FB, Li HJ, Nan YM, Sun DX.

World J Gastroenterol. 2014 Dec 28;20(48):18284-95. doi: 10.3748/wjg.v20.i48.18284.

6.

Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.

Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Zennou V, Otto MJ, Furman PA.

J Virol. 2011 Dec;85(23):12334-42. doi: 10.1128/JVI.05639-11. Epub 2011 Sep 28.

7.

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A.

Antimicrob Agents Chemother. 2004 Jun;48(6):2260-6.

8.

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.

Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J.

Arch Virol. 2013 Sep;158(9):1907-15. doi: 10.1007/s00705-013-1687-6. Epub 2013 Apr 4.

PMID:
23553458
10.

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.

Sheaffer AK, Lee MS, Hernandez D, Chaniewski S, Yu F, Falk P, Friborg J, Zhai G, McPhee F.

Antivir Ther. 2011;16(5):705-18. doi: 10.3851/IMP1825.

PMID:
21817192
11.

A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.

Ivanisenko NV, Mishchenko EL, Akberdin IR, Demenkov PS, Likhoshvai VA, Kozlov KN, Todorov DI, Gursky VV, Samsonova MG, Samsonov AM, Clausznitzer D, Kaderali L, Kolchanov NA, Ivanisenko VA.

PLoS One. 2014 Mar 18;9(3):e91502. doi: 10.1371/journal.pone.0091502. eCollection 2014.

12.

Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.

Madan V, Paul D, Lohmann V, Bartenschlager R.

Gastroenterology. 2014 May;146(5):1361-72.e1-9. doi: 10.1053/j.gastro.2014.01.055. Epub 2014 Jan 31.

PMID:
24486951
13.

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M.

Antimicrob Agents Chemother. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. Epub 2014 May 27.

14.

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.

Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, Jia L, Qiu D, Huang X, Altaf A, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8. doi: 10.1128/AAC.05977-11. Epub 2012 Jan 3.

16.

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.

Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, Bard J, Chopra R, Krishnamurthy G, Mansour T, O'Connell J.

Antimicrob Agents Chemother. 2008 Sep;52(9):3327-38. doi: 10.1128/AAC.00238-08. Epub 2008 Jun 16.

17.

Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.

Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O, Bartels DJ, Rao BG, Rijnbrand R, Kieffer TL.

Antimicrob Agents Chemother. 2014 Sep;58(9):5456-65. doi: 10.1128/AAC.03052-14. Epub 2014 Jun 30.

18.

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.

Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M.

Antimicrob Agents Chemother. 2012 Mar;56(3):1331-41. doi: 10.1128/AAC.05611-11. Epub 2011 Dec 27.

19.

Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.

Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, Klumpp K, Symons J, Cammack N, Jiang WR.

Antimicrob Agents Chemother. 2008 Dec;52(12):4356-69. doi: 10.1128/AAC.00444-08. Epub 2008 Oct 6.

20.

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).

Flint M, Mullen S, Deatly AM, Chen W, Miller LZ, Ralston R, Broom C, Emini EA, Howe AY.

Antimicrob Agents Chemother. 2009 Feb;53(2):401-11. doi: 10.1128/AAC.01081-08. Epub 2008 Oct 20.

Supplemental Content

Support Center